Navigation Links
Repligen Receives Orphan Drug Designation from the FDA for RG2833 for Friedreich's Ataxia
Date:5/24/2010

macodynamic response of various biomarkers in peripheral blood to RG2833.  RG2833 is a new chemical entity, which is the subject of a composition of matter patent application, which if allowed, will remain in force until 2029 prior to any patent term extensions.  RG2833 has been developed in collaboration with scientists from The Scripps Research Institute and a broad network of international scientific thought leaders.  Repligen's research efforts have been partially funded with grants from the Muscular Dystrophy Association, the Friedreich's Ataxia Research Alliance, GoFAR and the National Ataxia Foundation.  We are also evaluating HDAC-3 inhibitors in animal models of Huntington's disease and cognition.

About Friedreich's Ataxia

Friedreich's ataxia is an inherited neurodegenerative disease caused by a single gene defect that results in inadequate production of the protein frataxin.  Low levels of frataxin lead to degeneration of both the nerves controlling muscle movements in the arms and legs and the nerve tissue in the spinal cord.  Symptoms of Friedreich's ataxia typically emerge between the ages of five and fifteen and often progress to severe disability, incapacitation or loss of life in early adulthood.  Preclinical studies have shown that specific HDAC inhibitors increase production of the protein frataxin, and may have the potential to arrest disease progression in patients with Friedreich's ataxia.  At present, there are no effective treatments for Friedreich's ataxia.

About Repligen Corporation

Repligen Corporation is a biopharmaceutical company focused on the development of novel therapeutics for neurological disorders.  In addition, we are the world's leading supplier of recombinant Protein A, the sales of w
'/>"/>

SOURCE Repligen Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Repligen Announces Conference Call of Third Quarter Fiscal Year 2008 Results
2. Repligen Announces Settlement with Bristol-Myers Squibb in Orencia(R) Lawsuit
3. Repligen Reports Fourth Quarter and Fiscal Year 2008 Financial Results
4. Repligen Announces Conference Call of First Quarter Fiscal Year 2009 Results
5. Repligen Receives Research Grants to Support Friedreichs Ataxia Development Program
6. Repligen Announces Publication of Positive Results with Proprietary HDAC Inhibitor in Huntingtons Disease Model
7. Repligen to Present at the 2008 UBS Global Life Sciences Conference Wednesday, September 24th, 1:00 p.m. EDT
8. Repligen to Present at the Rodman & Renshaw 10th Annual Healthcare Conference Monday, November 10th, 4:55 p.m. EST
9. Repligen Announces Conference Call of Third Quarter Fiscal Year 2009 Results
10. Repligen to Present at the BIO CEO & Investor Conference Monday, February 9th, 11:30 a.m. EST
11. Repligen Reports Third Quarter Fiscal Year 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... (PRWEB) September 18, 2014 Pipette.com ... include Sartorius/Biohit, Socorex, Capp, and AccuPet brand of ... of 100 uL or less and are a ... forensic applications. , The micropipette promotions were ... and economic alternative products to help customers find ...
(Date:9/17/2014)... 17, 2014  PDL BioPharma, Inc. (PDL) (NASDAQ: ... firm, Ernst & Young LLP ("EY") that it was resigning ... letter delivered to the Company on September 15, 2014 and ... PDL has issued the following statement in ... number of inquiries on the reason for the resignation of ...
(Date:9/17/2014)... Sept. 17, 2014 /PRNewswire/ - Oncothyreon Inc. (NASDAQ: ... offer and sell shares of its Common Stock and ... underwritten public offerings.  The Series A Convertible Preferred Stock ... Stock, provided that conversion will be prohibited if, as ... own more than 4.99% of the Common Stock then ...
(Date:9/17/2014)... Shimadzu Scientific Instruments introduces ... which offers a powerful separation method for ... provides a new level of knowledge and ... to scientists analyzing pharmaceutical impurities, proteins, lipids, ... Comprehensive 2D-LC combines two independent separation modes ...
Breaking Biology Technology:Major Pipette Distributor Pipette.com Announces Promotions on Sartorius/Biohit, Socorex, Capp, and AccuPet Micropipettes 2Major Pipette Distributor Pipette.com Announces Promotions on Sartorius/Biohit, Socorex, Capp, and AccuPet Micropipettes 3PDL BioPharma Issues Statement on Resignation of Ernst and Young as Corporate Auditors 2PDL BioPharma Issues Statement on Resignation of Ernst and Young as Corporate Auditors 3Oncothyreon Announces Proposed Public Offerings 2Shimadzu’s New Nexera-e Two Dimensional Comprehensive Liquid Chromatograph Empowers Laboratories to Separate Even the Most Complex Mixtures 2
... 5 Onyx Pharmaceuticals,Inc. (Nasdaq: ONXX ) ... Annual,JPMorgan Healthcare Conference on Monday, January 12, at 11:00 ... webcast of the presentation on our,website at: http://www.onyx-pharm.com/wt/page/event_calendar ... that listeners log on 15 minutes early in order ...
... WESTFORD, Mass., Jan. 5 LightLab Imaging ... field this past year that are,the culmination ... the,company. These advances significantly increase the ... or OCT. OCT is a new,high-resolution, ...
... N.Y., Jan. 5 Theodosius Dobzhansky, the late great ... biology makes sense except in the light of evolution."This ... 12, 1809) and the 150th anniversary of the publication ... out the theory of evolution by means of natural ...
Cached Biology Technology:LightLab Imaging Leads Global Advancement of Intracoronary Imaging 2LightLab Imaging Leads Global Advancement of Intracoronary Imaging 3GEN Joins Charles Darwin 2009 Celebration 2
(Date:9/18/2014)... has found clownfish larvae can swim up to 400 kilometres ... to cope with environmental change. , Clownfish spend their entire ... as babies they must wander the open ocean, says study ... for Coral Reef Studies (Coral CoE) at James Cook University. ... but now we,ve been given a rare glimpse into how ...
(Date:9/17/2014)... in the creation of the Santa Ana Wildfire Threat ... threat potential of the powerful, hot, dry Santa Ana ... The index was introduced Sept. 17 by the U.S. ... Gas and Electric. , The index includes four classification ... used to help fire agencies and other emergency responders, ...
(Date:9/17/2014)... 2000 as an EC-FP5 four-year project, delivering its first ... and successful participations in several EC projects, as a ... project (EU BON), to increase the general awareness ... extend the general dissemination of the Fauna Europaea results, ... applied its novel e-Publishing tools to prepare data papers ...
Breaking Biology News(10 mins):Nemo's epic journey to find a new home 2UCLA scientists play key role in developing new Santa Ana Wildfire Threat Index 2Contributions on Fauna Europaea: Data papers as innovative model on expert involvement 2
... 4, 2007 Scientists from UC Irvine and CODA ... a common strain of yeast used in the production ... of ethanol. Researchers at UCIs Institute for ... gene-protein-production algorithms to tweak the genetic structure of a ...
... Bourns College of Engineering have received a four-year $2.2 ... to be shared with researchers at Arizona State University, ... roots of common diseases. Employing nanotechnology to create ... a new nationwide effort by NIH to better understand ...
... For the first time, scientists at Children,s Hospital of Pittsburgh ... cells derived from human muscle that could be used to ... muscular dystrophy. , In a study using human muscle tissue, ... Johnny Huard, PhD, and Bruno Pault, PhD - isolated and ...
Cached Biology News:UCI and CODA Genomics collaborate to re-engineer yeast for biofuel production 2UCI and CODA Genomics collaborate to re-engineer yeast for biofuel production 3UCR engineers to develop new tool to measure how environmental exposures affect health 2UCR engineers to develop new tool to measure how environmental exposures affect health 3Pittsburgh scientists identify human source of stem cells with potential to repair muscle 2Pittsburgh scientists identify human source of stem cells with potential to repair muscle 3
Rabbit polyclonal to Vitronectin ( Abpromise for all tested applications). Antigen: Full length native Vitronectin (Cow) Entrez Gene ID: 7448 Swiss Protein ID: P04004...
McCoy's 5A Medium. Without Tryptose or Phosphate Broth. Contains Sodium Bicarbonate....
... fast and specific detection of chromosomal sequences ... hybridisation time ( Works ... Multiplex capability Available with different tags ... available with different labels. Related Content: ...
... K-12 strain ideally suited as an initial ... efficiency, blue/white screening capability (with appropriate plasmids) ... high yields of excellent quality plasmid DNA. ... useful as a stringent host due to ...
Biology Products: